Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Zydus Lifesciences Ltd has been implicated in a recall of 23,304 bottles of Dapsone Gel 7.5%, a popular acne treatment ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Housing & Urban Development Corp., Paras Defence and Space Technologies Ltd. and Waaree Energies Ltd. are some stocks that ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Jio Financial Services and BlackRock further subscribed to Rs 5.85 crore shares of JV Jio BlackRock Asset Management for Rs ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...